BIO-TECHNE Corp Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount
BIO-TECHNE Corp (TECH) reported Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount of $50.54 million for the 12-month period ending 2026-06-30, per its 10-K filed 2026-08-24.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate · last filed 2026-08-24
- BIO-TECHNE Corp effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2026 was $50.54M.
- BIO-TECHNE Corp effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2017 was $39.19M, a 24.08% decline from fiscal 2016.
- BIO-TECHNE Corp effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2016 was $51.62M, a 4.33% decline from fiscal 2015.
- BIO-TECHNE Corp effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2015 was $53.96M, a 4.48% decline from fiscal 2014.
| Period end | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount 12 month |
|---|---|
| 2026-06-30 | $50.54M 10-K · filed 2026-08-24 |
| 2017-06-30 | $39.19M 10-K · filed 2017-09-07 |
| 2016-06-30 | $51.62M 10-K · filed 2017-09-07 |
| 2015-06-30 | $53.96M 10-K · filed 2017-09-07 |
| 2014-06-30 | $56.49M 10-K · filed 2016-08-29 |
| 2013-06-30 | $56.23M 10-K · filed 2015-08-31 |
| 2012-06-30 | $56.77M 10-K · filed 2014-08-29 |
| 2011-06-30 | $57.74M 10-K · filed 2013-08-29 |
| 2010-06-30 | $54.76M 10-K · filed 2012-08-29 |
| 2009-06-30 | $54.38M 10-K · filed 2011-08-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |